Septerna is about to find out how a biotech without “any meaningful clinical data” fares in the late 2024 IPO market. | ...

The FDA is getting the word out on a mandatory software update from Philips for its Trilogy line of portable life support ...

Synchron has reported that its miniature brain-computer interface implant, threaded up through the blood vessels to help read the activity of the motor cortex, showed no major side effects in a ...

Frazier Life Sciences has sourced a further $630 million for its fund focused on small and mid-cap biotechs. | Frazier Life ...

Lundbeck has tapped Charles River Laboratories’ artificial intelligence capabilities to aid the discovery of neuroscience ...

The COVID-19 pandemic made the public acutely aware of how vulnerable their noses are. | The COVID-19 pandemic made us ...

Zephyrm Bioscience is gusting toward the Hong Kong stock exchange, filing (PDF) for an IPO to bankroll phase 3 trials of its ...

Cardia’s ShortCut device, designed to open up previously implanted heart valves and clear a path for blood to flow into the ...

GE HealthCare has secured the FDA’s approval for an injectable, radioactive imaging agent that gives clinicians a clearer ...

Gritstone bio has brought in bankers to explore “potential value-maximizing strategies” after its phase 2 colorectal cancer ...

BioMarin is adding kindling to the R&D fire, striking a match with CAMP4 Therapeutics for rights to select two targets ...

Kailera Therapeutics has launched into the increasingly crowded obesity space with a portfolio of assets acquired from China ...